Once again, the FDA is reminding healthcare professionals that the intravenous antibacterial Tygacil (tigecycline) carries a higher risk of mortality than compared to that of other drugs used to treat a variety of serious infections.
Tygacil is used for the treatment of complicated skin and skin structure infections, complicated intra-abdominal infections, and community acquired pneumonia. Tygacil is not approved for the treatment of hospital-acquired pneumonia (including ventilator-associated pneumonia) or diabetic foot infection, which is where the highest mortality risk is encountered.
To report complications with Tygacil:
• Complete and submit the report Online: www.fda.gov/MedWatch/report.htm
• Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
For further information, go to: Tygacil (tigecycline): Label Change - Increased Mortality Risk
Leave a comment